HK1024490A1 - Pharmaceutical compositions containing an mpl ligand. - Google Patents

Pharmaceutical compositions containing an mpl ligand.

Info

Publication number
HK1024490A1
HK1024490A1 HK00103786A HK00103786A HK1024490A1 HK 1024490 A1 HK1024490 A1 HK 1024490A1 HK 00103786 A HK00103786 A HK 00103786A HK 00103786 A HK00103786 A HK 00103786A HK 1024490 A1 HK1024490 A1 HK 1024490A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
compositions containing
mpl ligand
mpl
ligand
Prior art date
Application number
HK00103786A
Other languages
English (en)
Inventor
David N Brems
Michael J Treuheit
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1024490A1 publication Critical patent/HK1024490A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK00103786A 1996-10-04 2000-06-22 Pharmaceutical compositions containing an mpl ligand. HK1024490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72612396A 1996-10-04 1996-10-04
PCT/US1997/016196 WO1998014476A1 (en) 1996-10-04 1997-09-12 Pharmaceutical compositions containing an mpl ligand

Publications (1)

Publication Number Publication Date
HK1024490A1 true HK1024490A1 (en) 2000-10-13

Family

ID=24917340

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103786A HK1024490A1 (en) 1996-10-04 2000-06-22 Pharmaceutical compositions containing an mpl ligand.

Country Status (7)

Country Link
JP (1) JP2001501619A (ja)
KR (1) KR100408229B1 (ja)
CN (1) CN1142940C (ja)
AU (1) AU4344697A (ja)
HK (1) HK1024490A1 (ja)
TW (1) TW561050B (ja)
WO (1) WO1998014476A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357513B1 (en) 1994-01-03 2013-01-22 Genentech, Inc. Nucleic acids encoding mpl ligand (thrombopoietin) and fragments thereof
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
CZ20021186A3 (cs) * 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
AU2001280161A1 (en) * 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
US7250274B2 (en) * 2002-12-13 2007-07-31 Zymogenetics, Inc. IL-21 production in prokaryotic hosts
CN101052312B (zh) 2003-07-07 2013-02-13 希尔氏宠物营养品公司 用于改进宠物中的氧化状态的组合物
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
MX2009006594A (es) * 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
AU2014201388C1 (en) * 2006-12-21 2017-02-02 Amgen Inc. Stable Buffered Formulations Containing Polypeptides
CN102552184A (zh) * 2012-02-16 2012-07-11 山东泉港药业有限公司 一种血小板生成素拟肽冻干制剂
KR20230041086A (ko) 2012-09-20 2023-03-23 모르포시스 아게 류마티스 관절염에 대한 치료
MA45381A (fr) * 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
AU2018370019A1 (en) * 2017-11-16 2020-05-07 Amgen Inc. Stable compositions of pegylated carfilzomib compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
WO1995026746A1 (en) * 1994-03-31 1995-10-12 Amgen Inc. Compositions and methods for stimulating megakaryocyte growth and differentiation
NZ303588A (en) * 1995-02-15 1999-02-25 Amgen Inc Mpl ligand analogs having one or more changed glycosylation sites uses for these ligand analogs and dna sequences encoding them
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only

Also Published As

Publication number Publication date
CN1239480A (zh) 1999-12-22
AU4344697A (en) 1998-04-24
CN1142940C (zh) 2004-03-24
WO1998014476A1 (en) 1998-04-09
KR100408229B1 (ko) 2003-12-01
JP2001501619A (ja) 2001-02-06
TW561050B (en) 2003-11-11
KR20000048905A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
HK1021313A1 (en) Tetrahydrolipstatin containing compositions.
ZA967034B (en) Pharmaceutical compositions.
ZA965190B (en) Pharmaceutical composition.
HUP9902455A3 (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
ZA984849B (en) Compositions.
ZA978178B (en) Composition.
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
EG24118A (en) Pharmaceutical compositions
HK1028352A1 (en) Solid pharmaceutical composition containing benzofurane derivatives.
ZA9710593B (en) Antisebum and antioxidant compositions containing gugulipid and fractions thereof.
IL139529A0 (en) Platinum complexes, processes for the preparation thereof and pharmaceutical compositions containing the same
HK1038884A1 (en) Medicinal compositions.
HK1024490A1 (en) Pharmaceutical compositions containing an mpl ligand.
HK1019757A1 (en) Synthetic polysaccharides, preparation method therefor and pharmaceutical compositions containing same.
GB9616672D0 (en) Pharmaceutical compositions
ZA9711567B (en) Compounds.
EP0674899A3 (en) Deodorant composition.
ZA968081B (en) Pharmaceutical composition.
ZA967499B (en) Cosmetic compositions containing tricholine citrate.
IL142534A0 (en) Pharmaceutical compositions containing an antigen-adjuvent
ZA9510506B (en) Anti-oxidant compositions.
ZA977327B (en) Pharmaceutical composition containing 4-oxobutanoic acids.
EP0684038A3 (en) Deodorising preparations.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100912